The Port Delivery System with ranibizumab (PDS)—a new paradigm for long-acting retinal drug delivery
The Port Delivery System with ranibizumab (PDS) is an innovative, investigational, ocular drug delivery system with the potential to reduce treatment burden in patients with retinovascular diseases. The PDS implant is a permanent, indwelling device designed to continuously deliver a customized formulation of ranibizumab. The PDS with ranibizumab 100 mg/mL with refill-exchanges every 24 weeks was compared with intravitreal ranibizumab 0.5 mg every 4 weeks in the ongoing phase 3 Archway trial. This presentation characterizes the in vitro ranibizumab release, active release rate, and level of retained ranibizumab within the implant over time, and report on refill-exchange efficiency.